



Freedom of Information request & West Norfolk CCG response

WN312 – Biologics Spend

Could you provide the following information for the below drugs for your CCG?

- The total spend in the last financial year 2013/14?
- The total projected spend for this financial year 2014/15?
- The current spend to date financial year 2014/15?

If possible, please enter the information into this table:

	Total spend 2013/14	Projected total spend 2014/15	Current spend to date 2014/15
Abatacept (Orencia)			
Adalimumab (Humira)			
Anakinra (Kineret)			
Certolizumab pegol (Cimzia)			
Etanercept (Enbrel)			
Golimumab (Simponi)			
Infliximab (Remicade)			
Rituximab (MabThera)			
Tocilizumab (RoActemra)			
Tofacitinib (Xeljanz)			
Ustekinumab (Stelara)			

In response to your request NHS West Norfolk CCG have been able to provide approximate total spends on the drugs listed for 2013/2014 and spend to date for 2014/15. This information is provided below:

	Total spend 2013/14	Projected total spend 2014/15	Current spend to date 2014/15
Abatacept (Orencia)			
Adalimumab (Humira)			
Certolizumab pegol (Cimzia)			
Etanercept (Enbrel)			
Golimumab (Simponi)			
Infliximab (Remicade)			
Tocilizumab (RoActemra)			
Ustekinumab (Stelara)			
Rituximab (MabThera)			
Tofacitinib (Xeljanz)	Not used		
Anakinra (Kineret)	Not used		
Approximate spend of all above where used	£2,152,100	N/A	£1,209,860

Please note however that as these drugs are hospital only, and not prescribed by GPs, to gain more detailed information you would be better served to contact the relevant hospitals; Norfolk and Norwich University Hospital and Queen Elizabeth Hospital, Kings Lynn. Further information can be found by clicking on the links below:

[Norfolk and Norwich University Hospital](#) and
[Queen Elizabeth Hospital, Kings Lynn](#)